---
layout: default
title: Andrographis Paniculata Whole Baptisia Tinctoria R
parent: 僅模型預測 (L5)
nav_order: 320
evidence_level: L5
indication_count: 0
---

# Andrographis Paniculata Whole Baptisia Tinctoria R
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Andrographis–Echinacea Herbal Combination: Insufficient Data for Repurposing Evaluation

## One-Sentence Summary

This product is a complex seven-component botanical formula containing Andrographis paniculata, Baptisia tinctoria, Beta vulgaris, Ceanothus americanus, Chelidonium majus, Echinacea spp., and Silybum marianum, with no registered indication on record in any jurisdiction queried.
The TxGNN model was unable to generate repurposing predictions for this candidate, as the combination lacks a DrugBank identifier and structured pharmacological entry required by the knowledge-graph pipeline.
As a result, **no predicted indication**, **no supporting clinical trials**, and **no literature evidence** are currently available for evaluation.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | No registered indication on record |
| Predicted New Indication | No prediction generated |
| TxGNN Prediction Score | N/A |
| Evidence Level | Below L5 — no model output produced |
| US Market Status | Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

No TxGNN repurposing prediction was generated for this candidate. The product is a seven-component botanical combination without a DrugBank identifier, which is a mandatory prerequisite for the TxGNN knowledge-graph pipeline. Without a unified drug node in the graph, the model cannot perform disease-node mapping or score candidate indications.

Detailed mechanism of action data is not available. Based on published ethnobotanical and phytopharmacological literature, certain individual components carry recognized biological associations: Andrographis paniculata and Echinacea spp. are broadly associated with immunomodulatory activity; Silybum marianum (milk thistle) and Chelidonium majus with hepatoprotective properties; and Baptisia tinctoria and Ceanothus americanus with lymphatic and immune-supporting roles. However, these associations exist at the single-herb level and have not been encoded into the TxGNN knowledge graph as a combination entry.

To generate a valid repurposing prediction, each active ingredient must first be individually mapped to a DrugBank identifier and its mechanism encoded in the knowledge graph. Only after that structural prerequisite is fulfilled can the pipeline score and rank candidate indications.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This candidate lacks the structured drug-identity data — DrugBank ID, mechanism of action, and registered indications — required to run the TxGNN repurposing pipeline or conduct a meaningful safety evaluation. Proceeding without resolving these gaps would produce unreliable or empty outputs.

**To proceed, the following is needed:**

- **Resolve DG001 (Blocking):** Identify whether this combination holds any approval in any jurisdiction; if a package insert exists, extract the contraindications and key warnings
- **Resolve DG002 (High):** Assign DrugBank identifiers to each of the seven botanical ingredients individually; decide whether to evaluate them as a unified combination or as separate single-agent candidates in the pipeline
- **Obtain MOA data** for each ingredient from DrugBank or published pharmacology literature, and encode each drug node in the knowledge graph
- **Re-run the TxGNN pipeline** after the above data gaps are closed to generate ranked predicted indications
- **Conduct drug–herb interaction review** once individual ingredient identities are confirmed, particularly for Andrographis paniculata and Silybum marianum, which have documented interactions with cytochrome P450 enzymes
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

